{"indexed":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:42:38Z","timestamp":1558640558690},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T00:00:00Z","timestamp":1271808000000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00198-010-1230-5","type":"article-journal","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T14:52:01Z","timestamp":1271775121000},"page":"363-367","source":"Crossref","is-referenced-by-count":10,"title":"Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget\u2019s disease of bone","prefix":"10.1007","volume":"22","author":[{"given":"S. A.","family":"Polyzos","sequence":"first","affiliation":[]},{"given":"J.","family":"Kountouras","sequence":"additional","affiliation":[]},{"given":"A. D.","family":"Anastasilakis","sequence":"additional","affiliation":[]},{"given":"I.","family":"Litsas","sequence":"additional","affiliation":[]},{"given":"M.","family":"Kita","sequence":"additional","affiliation":[]},{"given":"G.","family":"Arsos","sequence":"additional","affiliation":[]},{"given":"E.","family":"Moralidis","sequence":"additional","affiliation":[]},{"given":"E.","family":"Terpos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,4,21]]},"reference":[{"key":"1230_CR1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-008-0629-8","volume":"19","author":"JP Devogelaer","year":"2008","unstructured":"Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S (2008) Management of patients with Paget\u2019s disease: a consensus document of the Belgian Bone Club. Osteoporos Int 19:1109\u20131117","journal-title":"Osteoporos Int"},{"key":"1230_CR2","first-page":"424","volume":"4","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Anastasilakis AD, Terpos E (2009) Paget\u2019s disease of bone: emphasis on treatment with zoledronic acid. Exp Rev Endocrinol Metab 4:424\u2013434","journal-title":"Exp Rev Endocrinol Metab"},{"key":"1230_CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200008033430512","volume":"343","author":"A Halabe","year":"2000","unstructured":"Halabe A, Lifschitz BM, Azuri J (2000) Liver damage due to alendronate. N Engl J Med 343:365\u2013366","journal-title":"N Engl J Med"},{"key":"1230_CR4","first-page":"179","volume":"26","author":"C Carrere","year":"2002","unstructured":"Carrere C, Duval JL, Godard B, De Jaureguiberry JP, Ciribilli JM (2002) Severe acute hepatitis induced by alendronate. Gastroenterol Clin Biol 26:179\u2013180","journal-title":"Gastroenterol Clin Biol"},{"key":"1230_CR5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00198-007-0323-2","volume":"18","author":"B Yanik","year":"2007","unstructured":"Yanik B, Turkay C, Atalar H (2007) Hepatotoxicity induced by alendronate therapy. Osteoporos Int 18:829\u2013831","journal-title":"Osteoporos Int"},{"key":"1230_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0210-5705(01)70164-1","volume":"24","author":"C Serna Higuera de La","year":"2001","unstructured":"de La Serna Higuera C, Perez VA, Rodriguez GS, Martinez MJ, Betancourt GA, Martin AM (2001) Alendronate-induced hepatocellular lesion. Gastroenterol Hepatol 24:244\u2013246","journal-title":"Gastroenterol Hepatol"},{"key":"1230_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0300-2977(98)00109-0","volume":"53","author":"RJ Lieverse","year":"1998","unstructured":"Lieverse RJ (1998) Hepatitis after alendronate. Neth J Med 53:271\u2013272","journal-title":"Neth J Med"},{"key":"1230_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjmed.2006.04.032","volume":"120","author":"MB Phillips","year":"2007","unstructured":"Phillips MB (2007) Risedronate-induced Hepatitis. Am J Med 120:1\u20132","journal-title":"Am J Med"},{"key":"1230_CR9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s001980050205","volume":"10","author":"K Laitinen","year":"1999","unstructured":"Laitinen K, Taube T (1999) Clodronate as a cause of aminotransferase elevation. Osteoporos Int 10:120\u2013122","journal-title":"Osteoporos Int"},{"key":"1230_CR10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-008-0852-6","volume":"26","author":"A Avramidis","year":"2008","unstructured":"Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget\u2019s disease of bone. J Bone Miner Metab 26:635\u2013641","journal-title":"J Bone Miner Metab"},{"key":"1230_CR11","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353:898\u2013908","journal-title":"N Engl J Med"},{"key":"1230_CR12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jbmr.5650110206","volume":"11","author":"SA Khan","year":"1996","unstructured":"Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA (1996) Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 11:178\u2013182","journal-title":"J Bone Miner Res"},{"key":"1230_CR13","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/tx700151t","volume":"20","author":"F Dieterle","year":"2007","unstructured":"Dieterle F, Schlotterbeck G, Binder M, Ross A, Suter L, Senn H (2007) Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates. Chem Res Toxicol 20:1291\u20131299","journal-title":"Chem Res Toxicol"},{"key":"1230_CR14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","volume":"86","author":"DB Kimmel","year":"2007","unstructured":"Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022\u20131033","journal-title":"J Dent Res"},{"key":"1230_CR15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00520-009-0704-5","volume":"17","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Anastasilakis AD, Terpos E (2009) Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Cancer 17:1329\u20131330","journal-title":"Support Care Cancer"},{"key":"1230_CR16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/156652409787847191","volume":"72","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Kountouras J, Zavos C (2009) Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72:299\u2013314","journal-title":"Curr Mol Med"}],"container-title":"Osteoporosis International","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1230-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-010-1230-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1230-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:01:10Z","timestamp":1558638070000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,21]]},"references-count":16,"journal-issue":{"published-print":{"date-parts":[[2011,1]]},"issue":"1"},"alternative-id":["1230"],"URL":"http:\/\/dx.doi.org\/10.1007\/s00198-010-1230-5","relation":{"cites":[]},"ISSN":["0937-941X","1433-2965"],"subject":["Endocrinology, Diabetes and Metabolism"],"container-title-short":"Osteoporos Int"}